Public samples and current scale
Content revision 2026-09-13.1000 currently publishes 286 source-traceable medicine records. Product, market, dosage form, package identity and source status are represented separately.
- Read the 20-medicine U.S. sample guide first: inspect the exact medicine set, 78 product/package identities, field boundaries, formats, FAQ and 14-day institutional-pilot route
- Download the XLSX directly: bilingual core fields, field dictionary and formula-based acceptance sheet
- Download the matching JSON directly: nested U.S. product records and per-presentation sources for the same 20 medicines
- Human-readable sample: Lipitor / atorvastatin
- Cross-market sample: CRAVIT / LEVAQUIN / 可乐必妥
- Single-record JSON sample
- Published medicine-record index
- API, locale, version and resource manifest
The r865 sample now matches the minimum pilot scope of 20 medicines, one market, bilingual core fields and JSON plus XLSX. It contains no patient or prescription data and makes no individual dose, stopping/switching, authentication, live-stock, reimbursement or pricing conclusion. Source access can change after review.
Core field dictionary
idStable record identifier for routes, APIs and version comparison.
namesBrand, non-proprietary and Chinese names, plus reviewed market-name cues.
marketScopeRegulatory market and label or historical-record scope.
presentationIdentitiesExact strengths, forms, routes, packs, product codes and image status.
labelReadingPlain-language larger-text label reading with the official source document.
pharmacovigilanceProduct label, reviewed safety records and official market safety routes.
sourcesPrimary URLs, source type, document date, review date and access status.
contentRevisionContent version for determining whether a client update is required.
Three delivery modes
- Evidence materials: JSON, tabular or reader-facing material scoped by medicine, market, language and fields.
- Source and version maintenance: agreed checks of link health, label versions, regulatory records and change logs.
- Embedding and accessibility assessment: field mapping, display boundaries, reading size, keyboard, mobile and print acceptance.
PAID PILOT OPTIONS
Start with a bounded, reviewable pilot
Each pilot freezes the medicine list, markets, fields, sources, version and acceptance criteria before work begins. Pricing is confirmed only after scope review; no public medicine ranking or editorial conclusion can be purchased.
Evidence data pilot
- Best for
- For patient-information, pharmacy, insurance and health-technology teams validating a structured evidence feed.
- Minimum starting scope
- One-off data pilot starting with 20 records
- Scope baseline
- A named set of medicines, target markets and bilingual fields agreed in writing.
- Pilot deliverables
- Field dictionary, sample JSON/XLSX delivery, source register, content revision and exception log.
- Acceptance evidence
- Required fields present; every factual field returns to its agreed source and market; exceptions are explicitly listed.
Source-change monitoring pilot
- Best for
- For teams that already maintain medicine content and need a controlled update watchlist.
- Minimum starting scope
- Monthly review of 20 medicine × market × source combinations
- Scope baseline
- A named medicine × market × source watchlist with an agreed review frequency.
- Pilot deliverables
- Link-health record, version comparison, dated change register and review summary.
- Acceptance evidence
- Every reported change identifies the previous and current source, review date, affected field and unresolved question.
Embedding and accessibility pilot
- Best for
- For websites or public-information services assessing reuse of source-linked medicine content.
- Minimum starting scope
- Bilingual mobile acceptance for one real page workflow
- Scope baseline
- A named page or component set, target devices, languages and accessibility checks.
- Pilot deliverables
- Field mapping, display-boundary specification, keyboard/mobile/text-size review and implementation findings.
- Acceptance evidence
- The agreed workflow is operable on target devices and preserves source, market, date and safety boundaries.
CONTINUING SERVICE
Move from a pilot to a reviewable maintenance rhythm
These are scope patterns, not fixed-price plans. The medicine list, markets, sources, review windows, deliverables, acceptance evidence and response boundary must be agreed in writing before service begins.
Quarterly evidence maintenance
- Review rhythm
- Scheduled review once per quarter
- Included evidence work
- Review agreed source links and document versions; issue a dated change register, exception list and content-revision summary.
- Best fit
- For a stable published medicine set that needs periodic evidence maintenance rather than continuous surveillance.
Monthly source monitoring
- Review rhythm
- Scheduled review once per month
- Included evidence work
- Review the agreed medicine × market × source watchlist; identify version or link changes and place material items into a priority review queue.
- Best fit
- For services with a higher update cadence and a defined source watchlist. It is not real-time safety monitoring.
Event-driven review add-on
- Review rhythm
- Review after an agreed official-source trigger
- Included evidence work
- Assess the named official notice or label update, record affected fields and unresolved questions, and issue an auditable update note.
- Best fit
- For organizations that need a bounded response workflow around defined regulatory or label events.
Fees, taxes, source licences, delivery windows, support level, SLA and renewal terms remain subject to a mutually confirmed written scope and final financial confirmation.
Acceptance approach
Each pilot first freezes the medicine list, markets, fields, languages, source-licence boundaries, content revision and review date. Acceptance then works through the agreed sample item by item. Scoping depends on medicine and market count, languages, field depth, update frequency and delivery format; pricing remains subject to final financial confirmation.
The service does not produce individual diagnosis, dosing, stopping/switching, combination or authentication conclusions. A collaborator cannot buy or alter public editorial conclusions, ranking or source standards.
PROCUREMENT FAQ
Questions a buyer should resolve before a paid pilot
These answers define the service boundary before any quotation or purchase. They are not medicine-use advice.
What can an organization purchase?
A bounded evidence-data deliverable, official-source and version maintenance, or an embedding and accessibility assessment. The written scope identifies medicines, markets, languages, fields, source boundaries, outputs and acceptance checks.
Is OriginDrug selling medicines or providing prescribing decisions?
No. This service does not sell or dispense medicines and does not provide individual diagnosis, dosing, substitution, stopping, combination, authentication or emergency safety decisions.
What is included in a first paid pilot?
An agreed medicine and market list, field dictionary, source register, content revision, review date, known gaps and exceptions, delivery files and an item-by-item acceptance checklist.
What information is needed to prepare a scope?
Organization and public website, medicine set or approximate record count, target markets, required languages, delivery format, expected timing, update cadence and acceptance needs.
How is a quotation determined?
Scope is driven by medicine count, market count, languages, field depth, source complexity, update frequency, output format and support. Amounts remain subject to final financial confirmation and a written scope.
When can work begin?
After both sides confirm the written scope, acceptance method, permitted source use, support boundary and final commercial terms. OriginDrug does not promise an unreviewed fixed turnaround.
Can a buyer change public rankings or editorial conclusions?
No. Commercial work cannot buy or alter public editorial conclusions, ranking, source standards or the display of evidence gaps.
Does the enquiry require personal or medical data?
No. Do not send patient names, medicine lists tied to a person, prescriptions, pack photographs, medical records, identity documents or payment information.
Is source monitoring a real-time pharmacovigilance alert service?
No. It is a bounded scheduled or event-triggered review of agreed official sources. It is not emergency monitoring and does not replace regulators, manufacturers, clinicians or local pharmacovigilance procedures.
What happens after the pilot?
The buyer may stop after acceptance or agree in writing to monthly, quarterly or event-triggered maintenance. No recurring service starts automatically.
SCOPE BUILDER
Turn your scope into a reviewable enquiry
Start with five essentials: organization or website, work email, intended use, target market and an approximate medicine scope. Optional details can be agreed after OriginDrug returns a scope suggestion. This page prepares a copyable summary or email draft; opening a draft does not send it.
Fill a minimum pilot scope in one click
Choose the closest starting point. We fill empty fields and update unedited suggestions, while keeping your edits and the medicine carried from its record. Add the organization, work email and target market, then review the draft.